WuXi Biologics Cayman. has been granted a patent for novel anti-PD-1 antibodies that target cell surface PD-1. The patent includes details on the nucleic acid molecules, expression vectors, host cells, and methods for producing these antibodies, along with a specific binding VHH molecule sequence. GlobalData’s report on WuXi Biologics Cayman gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi Biologics Cayman, Personalized cancer vaccines was a key innovation area identified from patents. WuXi Biologics Cayman's grant share as of June 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Novel anti-pd-1 antibodies and their production methods
The granted patent US12030941B2 outlines a novel Programmed Death 1 (PD-1) binding VHH molecule characterized by specific Complementarity Determining Regions (CDRs). The claims detail that the VHH molecule includes defined amino acid sequences for CDR1, CDR2, and CDR3, specifically referencing SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15. Additionally, the patent encompasses variations of the VHH molecule that maintain a high degree of sequence identity to a specified sequence (SEQ ID NO: 42) or allow for minor modifications through amino acid substitutions, deletions, or additions. The patent also includes claims for isolated nucleic acid molecules encoding the VHH, expression vectors, and host cells suitable for producing the VHH molecule.
Furthermore, the patent describes pharmaceutical applications of the PD-1 binding VHH molecule, including its use in compositions for therapeutic administration to inhibit the binding of PD-L1 or PD-L2 to PD-1 in human subjects. Methods for preparing the VHH molecule through expression in various cell types and subsequent isolation are also detailed. The claims extend to treatment methods for patients with tumors expressing PD-L1, as well as the development of kits for diagnosing or treating proliferative disorders or cancers. Notably, the VHH molecule may also be fused to other proteins, enhancing its potential utility in therapeutic and diagnostic applications.
To know more about GlobalData’s detailed insights on WuXi Biologics Cayman, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
